Thrice-weekly Copaxone has more merit than the failed “low-volume” Copaxone, which was never more than a gimmick, IMO. However, the thrice-weekly product is being tested at 40mg—twice the dose of regular Copaxone—and hence the FDA will likely consider it a distinct drug from regular Copaxone.
Final results of the GALA study testing thrice-weekly Copaxone are not expected until May 2014 (http://clinicaltrials.gov/ct2/show/NCT01067521 ), so the product probably can’t reach the US market until 2016 at the earliest. All told, potential competition from this product is far down on my list of concerns as a MNTA investor.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.